Patents by Inventor Paul O'Shea

Paul O'Shea has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200048266
    Abstract: The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.
    Type: Application
    Filed: August 15, 2019
    Publication date: February 13, 2020
    Inventors: Elyse BOURQUE, Mario CABRERA-SALAZAR, Cassandra CELATKA, Seng CHENG, Mary A. CROMWELL, Andrew GOOD, Bradford HIRTH, Katherine JANCSICS, John P. LEONARD, Lingyun LI, James LILLIE, Hanlan LIU, Elina MAKINO, John MARSHALL, Paul MASON, Markus METZ, Fazeela MORSHED, Thomas O'SHEA, Ronald SCHEULE, Renato SKERLJ, Bing WANG, Yibin XIANG, Zhong ZHAO
  • Patent number: 8674093
    Abstract: The present invention is directed to processes for preparing a pyridyl piperidine compound which is an antagonist of orexin receptors, and which is useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
    Type: Grant
    Filed: May 18, 2009
    Date of Patent: March 18, 2014
    Assignees: Merck Canada Inc., Merck Sharp & Dohme Corp.
    Inventors: Louis-Charles Campeau, John Y. Chung, Danny Gauvreau, Melina Girardin-Rondeau, Gregory Hughes, Kevin M. Maloney, Christophe Mellon, Jeffrey C. Moore, Paul O'Shea, Stephane Ouellet
  • Patent number: 8273913
    Abstract: This invention describes an amidation process whereby amino acids of the Formulae IIA or IIB can be activated and treated with an amine in the presence of a base to yield amides of the Formula (I), without loss of optical purity.
    Type: Grant
    Filed: March 31, 2008
    Date of Patent: September 25, 2012
    Assignee: Merck Canada Inc.
    Inventors: Paul O'Shea, Francis Gosselin
  • Publication number: 20120035214
    Abstract: The present invention relates to biaryl piperidine-based renin inhibitor compounds, and their use in treating cardiovascular events and renal insufficiency.
    Type: Application
    Filed: April 1, 2010
    Publication date: February 9, 2012
    Applicants: Merck Canada Inc., Merck Sharp & Dohme Corp.
    Inventors: Daniel J. McKay, Melissa Arbour, Renee Aspiotis, Austin Chen, Pierre-Andre Fournier, Michel Gallant, Yongxin Han, Helene Juteau, Patrick Lacombe, Sebastien Laliberte, Sophie Lauzon, Carmela Molinaro, Paul O'Shea, Yeeman Ramtohul, Daniel Simard, Dwight MacDonald, Bruce Mackay, Christophe Mellon, Krista Morley, Chit Tsui, Sarah Jennifer Dolman, Greg Hughes, Jacob Janey
  • Publication number: 20110165632
    Abstract: The present invention is directed to processes for preparing a pyridyl piperidine compound which is an antagonist of orexin receptors, and which is useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
    Type: Application
    Filed: May 18, 2009
    Publication date: July 7, 2011
    Inventors: Louis-Charles Campeau, John Y. Chung, Danny Gauvreau, Melina Girardin-Rondeau, Gregory Hughes, Kevin M. Maloney, Christophe Mellon, Jeffrey C. Moore, Paul O'Shea, Stephane Quellet
  • Publication number: 20110105798
    Abstract: The instant invention involves the enantioselective hydrogenation of isomeric N—H imines (N-unsubstituted) using a transition metal based catalyst modified with a chiral phosphine derivative to produce enantiomerically enriched chiral amines.
    Type: Application
    Filed: June 22, 2009
    Publication date: May 5, 2011
    Inventors: Paul O'Shea, Francis Gosselin, James C. Mcwilliams
  • Publication number: 20100305080
    Abstract: The present application relates to crystalline 1,2-ethanedisulfonic acid salt and N,N?-dibenzylethylenediamine salt of montelukast. The salts are useful as therapeutic agents for the treatment of leukotriene mediated diseases and disorders. This application also relates to processes and intermediates for preparing the said salts and pharmaceutical compositions comprising the salts and optionally other therapeutic agents.
    Type: Application
    Filed: October 23, 2008
    Publication date: December 2, 2010
    Inventor: Paul O'Shea
  • Publication number: 20100130782
    Abstract: This invention describes an amidation process whereby amino acids of the Formulae IIA or IIB can be activated and treated with an amine in the presence of a base to yield amides of the Formula (I), without loss of optical purity.
    Type: Application
    Filed: March 31, 2008
    Publication date: May 27, 2010
    Applicant: MERCK FROSST CANADA LTD.
    Inventors: Paul O'Shea, Francis Gosselin
  • Patent number: 7183425
    Abstract: This invention describes a reductive amination process whereby perfluorinated ketones or ketals are combined with ?-aminoesters under basic conditions to form metal carboxylates. Diastereoselective reductions of the metal carboxylates enable access to two diastereomers, depending on the reducing conditions.
    Type: Grant
    Filed: July 29, 2005
    Date of Patent: February 27, 2007
    Assignee: Merck Frosst Canada Ltd.
    Inventors: Cheng Yi Chen, Paul N. Devine, Bruce S. Foster, Greg Hughes, Paul O'Shea
  • Patent number: 7154005
    Abstract: This invention describes the reaction of an alpha fluoroalkyl ketone with a bis(trialkylsilyl)amide to give a stable N-trialkylsilyl imine. Treatment of the N-trialkylsilyl imine with an alcohol leads to solvolysis of the trialkylsilyl group and yields a stable mixture of an aminal and an imine in high yield. Catalytic reduction of this mixture, or of the individual components, in the presence of a chiral catalyst leads to a fluoroalkyl amine with high enantioselectivity and high yield.
    Type: Grant
    Filed: September 7, 2005
    Date of Patent: December 26, 2006
    Assignee: Merck Frosst Canada, Ltd.
    Inventors: Paul O'Shea, Francis Gosselin
  • Patent number: 7049295
    Abstract: The invention provides the use of a compound capable of preferential interaction with plasma membrane lipid microdomains (PMLMs) as enhancers of transport processes across endothelial, epithelial and mesothelial membranes (ie including blood-brain-blood barrier and gastrointestinal mucosal membranes). When associated with therapeutic agents, the compounds act as transport vehicles. When the compounds interact with PMLMs in such a way as to inhibit transport across the membrane, the compounds function as anti-infective agents.
    Type: Grant
    Filed: December 21, 2000
    Date of Patent: May 23, 2006
    Assignee: Biotransys Limited
    Inventors: Roy Harris, Paul O'Shea
  • Publication number: 20060052642
    Abstract: This invention describes the reaction of an alpha fluoroalkyl ketone with a bis(trialkylsilyl)amide to give a stable N-trialkylsilyl imine. Treatment of the N-trialkylsilyl imine with an alcohol leads to solvolysis of the trialkylsilyl group and yields a stable mixture of an aminal and an imine in high yield. Catalytic reduction of this mixture, or of the individual components, in the presence of a chiral catalyst leads to a fluoroalkyl amine with high enantioselectivity and high yield.
    Type: Application
    Filed: September 7, 2005
    Publication date: March 9, 2006
    Inventors: Paul O'Shea, Francis Gosselin
  • Publication number: 20060030731
    Abstract: This invention describes a reductive amination process whereby perfluorinated ketones or ketals are combined with ?-aminoesters under basic conditions to form metal carboxylates. Diastereoselective reductions of the metal carboxylates enable access to two diastereomers, depending on the reducing conditions.
    Type: Application
    Filed: July 29, 2005
    Publication date: February 9, 2006
    Inventors: Cheng Chen, Paul Devine, Bruce Foster, Greg Hughes, Paul O'Shea
  • Publication number: 20040235719
    Abstract: A protein polymer is soluble in aqueous media and retains the native ligand binding properties of the protein. The polymer comprises two or more protein monomer units, such as albumin molecules, that are covalently bound through coupling agents that give rise to spacer chains of atoms between the protein molecules. The spacer chains preferably have a length of at least twenty atoms. The protein polymers are suitable for pharmaceutical drug delivery of physiologically active molecules by a variety of routes.
    Type: Application
    Filed: June 28, 2004
    Publication date: November 25, 2004
    Inventors: Roy Harris, Paul O'Shea
  • Publication number: 20030166545
    Abstract: The invention provides the use of a compound capable of preferential interaction with plasma membrane lipid microdomains (PMLMs) as enhancers of transport processes across endothelial, epithelial and mesothelial membranes (ie including blood-brain-blood barrier and gastrointestinal mucosal membranes). When associated with therapeutic agents, the compounds act as transport vehicles. When the compounds interact with PMLMs in such a way as to inhibit transport across the membrane, the compounds function as anti-infective agents.
    Type: Application
    Filed: October 8, 2002
    Publication date: September 4, 2003
    Inventors: Roy Harris, Paul O'Shea
  • Patent number: 6495713
    Abstract: This invention encompasses a process for making a compound of Formula A These compounds are intermediates useful in the preparation of certain non-steroidal anti-inflammnatory agents.
    Type: Grant
    Filed: January 17, 2002
    Date of Patent: December 17, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Cheng Yi Chen, Weirong Chen, Paul O'Shea, Lushi Tan, Richard Tillyer, Feng Xu, Philippe Dagneau
  • Publication number: 20020143205
    Abstract: This invention encompasses a process for making a compound of Formula A 1
    Type: Application
    Filed: January 17, 2002
    Publication date: October 3, 2002
    Inventors: Cheng Yi Chen, Weirong Chen, Paul O'Shea, Lushi Tan, Richard Tillyer, Feng Xu, Philippe Dagneau
  • Patent number: 6420565
    Abstract: 2-lithio-5-halopyridine is formed as a predominant component of a reaction mixture by reacting BuLi with 2,5-dihalopyridine in a non-coordinating solvent.
    Type: Grant
    Filed: February 27, 2001
    Date of Patent: July 16, 2002
    Assignees: Merck & Co., Inc., Merck Frosst Canada & Co
    Inventors: Paul O'Shea, Xin Wang, Richard Tillyer
  • Publication number: 20020016470
    Abstract: 2-lithio-5-halopyridine is formed as a predominant component of a reaction mixture by reacting BuLi with 2,5-dihalopyridine in a non-coordinating solvent.
    Type: Application
    Filed: February 27, 2001
    Publication date: February 7, 2002
    Inventors: Paul O'Shea, Xin Wang, Richard Tillyer
  • Patent number: 6281391
    Abstract: This invention encompasses a novel process for synthesizing compounds represented by formula A: These compounds are intermediates useful in the preparation of certain agents that are selective COX-2 inhibitors.
    Type: Grant
    Filed: October 27, 1999
    Date of Patent: August 28, 2001
    Assignees: Merck & Co., Inc., Merck Frosst Canada & Co.
    Inventors: Richard D. Tillyer, Ian W. Davies, Robert D. Larsen, Xin Wang, Paul O'Shea, Anthony On-Ping King, Dalian Zhao, Cheng Y. Chen, Edward J. J. Grabowski